Anti-human Ketamine (KET) human monoclonal antibody (mAb)
1953
GMP-SMT-234-Ag-1
BSA-Ketamine (KET)
756
GMP-SMT-234-Ag-2
OVA-Ketamine (KET)
756
GMP-SMT-234-Ab-1
Anti-Ketamine (KET) mouse monoclonal antibody
1953
GMP-SMT-234-Ab-2
Anti-Ketamine (KET) human monoclonal antibody
1953
Size： 1mg |
10mg | 100mg
Product Description
Cat No. of Products
GMP-SMT-234-Ag01, GMP-SMT-234-Ag-1
Product Name
BSA-Ketamine (KET)
Target/Biomarker
Ketamine (KET)
Expression platform
Synthetic
Isotypes
NA
Bioactivity validation
Ketamine
(KET) antibodies
binding, Immunogen in Sandwich Elisa, lateral-flow
tests, and other immunoassays as control material in
KET level test of
Pain (depression and PTSD) and related
syndrome evaluation.
Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage
Store at
-20℃ to -80℃ under sterile conditions. Avoid
repeated freeze-thaw cycles.
Cat No. of Products
GMP-SMT-234-Ag02, GMP-SMT-234-Ag-2
Product Name
OVA-Ketamine (KET)
Target/Biomarker
Ketamine (KET)
Expression platform
Synthetic
Isotypes
NA
Bioactivity validation
Ketamine
(KET) antibodies
binding, Immunogen in Sandwich Elisa, lateral-flow
tests, and other immunoassays as control material in
KET level test of
Pain (depression and PTSD) and related
syndrome evaluation.
Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage
Store at
-20℃ to -80℃ under sterile conditions. Avoid
repeated freeze-thaw cycles.
Ketamine
(KET) antibodies
binding, Immunogen in Sandwich Elisa, lateral-flow
tests, and other immunoassays as control material in
KET level test of
Pain (depression and PTSD) and related
syndrome evaluation.
Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage
Store at
-20℃ to -80℃ under sterile conditions. Avoid
repeated freeze-thaw cycles.
Cat No. of Products
GMP-SMT-234-Ab02
Product Name
Anti-human Ketamine (KET) human monoclonal antibody (mAb)
Target/Biomarker
Ketamine (KET)
Expression platform
Hybridoma
Isotypes
Mouse IgG
Bioactivity validation
Ketamine
(KET) antibodies
binding, Immunogen in Sandwich Elisa, lateral-flow
tests, and other immunoassays as control material in
KET level test of
Pain (depression and PTSD) and related
syndrome evaluation.
Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage
Store at
-20℃ to -80℃ under sterile conditions. Avoid
repeated freeze-thaw cycles.
Cat No. of Products
GMP-SMT-234-Ab-1
Product Name
Anti-Ketamine (KET) mouse monoclonal antibody
Target/Biomarker
Ketamine (KET)
Expression platform
Bioactivity validation
Ketamine
(KET) antibodies
binding, Immunogen in Sandwich Elisa, lateral-flow
tests, and other immunoassays as control material in
KET level test of
Pain (depression and PTSD) and related
syndrome evaluation.
ELISA tests and other immunoassays; Lateral flow immunoassay (LFIA); LTIA; Immunonephelometry; Time-resolved Fluorescence Immunoassay (TRFIA)
Formulation & Reconstitution
Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage
Store at
-20℃ to -80℃ under sterile conditions. Avoid
repeated freeze-thaw cycles.
Cat No. of Products
GMP-SMT-234-Ab-2
Product Name
Anti-Ketamine (KET) human monoclonal antibody
Target/Biomarker
Ketamine (KET)
Expression platform
Bioactivity validation
Ketamine
(KET) antibodies
binding, Immunogen in Sandwich Elisa, lateral-flow
tests, and other immunoassays as control material in
KET level test of
Pain (depression and PTSD) and related
syndrome evaluation.
ELISA tests and other immunoassays; Lateral flow immunoassay (LFIA); LTIA; Immunonephelometry; Time-resolved Fluorescence Immunoassay (TRFIA)
Formulation & Reconstitution
Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage
Store at
-20℃ to -80℃ under sterile conditions. Avoid
repeated freeze-thaw cycles.
Reference
Validation Data
Click
to get more
Data / Case study about the product.
Target/Biomarker information
1. What is Ketamine, and How Does it Relate to In Vitro Diagnosis (IVD)?
Ketamine, chemically known as (RS)-2- (2-Chlorophenyl)-2- (methylamino)cyclohexanone, is a pharmacologically diverse compound renowned for its versatile clinical applications. Principally, it is recognized for its efficacy as a dissociative anesthetic agent. Ketamine induces a unique trance-like state characterized by profound analgesia, sedation, and amnesia while preserving cardiovascular stability. Due to these distinctive properties, Ketamine is employed in a variety of medical contexts, ranging from surgical anesthesia to acute pain management and sedation during medical procedures.
Within the realm of in vitro diagnosis (IVD), Ketamine assumes a secondary and auxiliary role. Unlike traditional diagnostic markers or analytes, Ketamine is not typically measured in IVD tests to diagnose specific medical conditions or diseases. Instead, Ketamine's significance in IVD lies in the context of patient management and surveillance during medical interventions where it is administered.
Healthcare practitioners and anesthesiologists utilize various IVD techniques and monitoring instruments to assess a patient's vital signs, oxygen saturation levels, and other pertinent physiological parameters during Ketamine administration. These diagnostics serve the crucial purpose of upholding patient well-being and fine-tuning drug dosages to maintain the desired sedative or anesthetic effect. Consequently, Ketamine indirectly influences IVD by mandating continuous monitoring throughout its administration in clinical settings.
2. The Importance of Monitoring Ketamine Administration
Monitoring Ketamine itself is not a routine practice in IVD, as it is not typically used as a direct diagnostic marker for specific medical conditions. Instead, the emphasis is placed on supervising the patient's physiological responses and vital metrics during Ketamine infusion. Several pivotal reasons underscore the necessity of monitoring Ketamine administration:
a. Safety: Ketamine is known for its potent anesthetic properties, which can induce profound sedation. Therefore, vigilant monitoring of vital signs, such as heart rate, blood pressure, respiratory rate, and oxygen saturation, is indispensable to ensure patient safety during medical procedures that involve Ketamine administration.
b. Dosage Adjustment: Tailoring the Ketamine dosage to meet the patient's specific requirements and the demands of the medical procedure is paramount. Continuous monitoring enables real-time assessment and necessary dosage adaptations to achieve the desired level of sedation or anesthesia.
c. Optimal Anesthesia: Maintaining the desired depth of anesthesia is critical during medical procedures. Monitoring facilitates the continuous assessment of a patient's level of sedation or anesthesia, ensuring that they remain comfortable and pain-free throughout the procedure.
d. Adverse Reaction Detection: While Ketamine is generally considered safe, it may occasionally elicit adverse reactions or side effects in some patients. Swiftly detecting any complications, such as hallucinations, delirium, or respiratory distress, through vigilant monitoring allows for immediate intervention and mitigation of these side effects.
e. Individualized Care: Patients exhibit varying responses to Ketamine due to factors such as age, weight, and underlying medical conditions. Monitoring empowers healthcare providers to customize treatment, optimizing the sedation or anesthesia level according to each patient's unique requirements, thereby ensuring their safety and comfort.
In summary, while direct measurement of Ketamine is not the primary focus of IVD, monitoring Ketamine administration is pivotal. It guarantees patient safety, anesthesia optimization, and timely responses to variations or adverse reactions during medical procedures where Ketamine is employed. Continuous monitoring ensures that patients receive individualized care, enhancing the overall quality of medical interventions involving Ketamine.
About GDU
GDU helps global diagnostic partners in high
quality of raw material discovery,
development, and application. GDU believes in
Protein&antibody Innovation for more
reliable diagnostic solutions.
Go to Pain diagnostics products collection
>>
Facebook
LinkedIn
Twitter
Comments
No comments yet.